Table 1.
Comparison of metabolic parameters and serum levels of fibroblast growth factor 21 (FGF21) between the control and papillary thyroid cancer (PTC) groups.
| Variable | Control Group (n = 52) | PTC Group (n = 127) | p-Value |
|---|---|---|---|
| Age (years) | 52.0 ± 12.3 | 50.5 ± 12.2 | 0.488 |
| Sex (male:female) | 9:31 | 18:109 | 0.212 |
| Body weight (kg) | 62.5 ± 11.4 | 61.2 ± 9.5 | 0.519 |
| Height (cm) | 160.4 ± 9.5 | 158.0 ± 8.1 | 0.102 |
| BMI (kg/m2) | 23.5 ± 2.7 | 24.5 ± 3.1 | 0.060 |
| Systolic blood pressure (mmHg) | 118.7 ± 9.4 | 117.7 ± 8.0 | 0.053 |
| Diastolic blood pressure (mmHg) | 74.0 ± 8.9 | 75.2 ± 5.9 | 0.318 |
| Fasting glucose (mm) | 99.9 ± 9.9 | 96.4 ± 15.4 | 0.174 |
| Triglycerides (mm) | 137.2 ± 116.1 | 136.2 ± 83.7 | 0.961 |
| Total cholesterol (mm) | 184.1 ± 32.7 | 187.9 ± 36.7 | 0.532 |
| LDL cholesterol (mm) | 111.3 ± 29.9 | 112.1 ± 36.0 | 0.895 |
| HDL cholesterol (mm) | 52.8 ± 13.1 | 51.6 ± 12.4 | 0.623 |
| AST (IU/L) | 21.1 ± 6.2 | 19.5 ± 7.2 | 0.185 |
| ALT (IU/L) | 20.3 ± 14.1 | 20.3 ± 12.4 | 0.895 |
| TSH (IU/mL) | 2.2 ± 1.9 | 2.2 ± 3.8 | 0.993 |
| Serum level of FGF21 (pg/mL) | 147.4 ± 68.7 | 227.2 ± 184.0 | 0.017 * |
Abbreviations: FGF, fibroblast growth factor; PTC, papillary thyroid cancer; BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein; AST, aspartate transaminase; ALT, alanine transaminase; TSH, thyroid stimulating hormone; IU, international unit. Data are presented as the mean ± SD. p-values from the unpaired t-test for continuous parametric variables or the Mann–Whitney U test for nonparametric variables. * p < 0.05.